张鸿,王梓凝,李怀瑾,朱珊,赵宇彤,龚艳君,蒋捷

• 1:北京大学第一医院麻醉与重症医学科
• 2:北京大学第一医院药学部
• 3:北京大学第一医院心血管内科

摘要(Abstract)：

目的调查北京大学第一医院术前长期服用抗血栓药物患者的围术期药物管理情况,并分析与围术期主要不良心脑血管事件(MACCE)、出血事件相关的危险因素。方法本研究为前瞻性队列研究,收集2018年10月1日至2019年2月28日在北京大学第一医院进行外科手术、且术前长期服用抗血栓药物患者的相关信息,观察并记录围术期抗血栓药物管理情况、患者住院期间的MACCE和出血事件。结果最终有372例患者进入分析。364例(97.8%)患者在术前停用抗血栓药物,仅3例患者在进行出血低风险手术前未停药;服用阿司匹林的311例患者中,188例(60.5%)患者术前阿司匹林停药时间大于7 d;49.5%(47/95)服用P2Y12受体抑制剂的患者术前使用低分子肝素进行桥接。围术期共发生MACCE 16例(4.3%),出血事件10例(2.7%)。多因素Logistic分析发现年龄>65岁(OR 5.800,95%CI 1.243～27.070,P=0.025)、外周动脉疾病(OR 6.090,95%CI 1.380～26.878,P=0.017)和4级手术(OR 6.144,95%CI1.191～31.701,P=0.030)为围术期MACCE的独立危险因素;术前服用阿司匹林+替格瑞洛的抗血小板治疗方案(OR 14.110,95%CI 1.743～114.188,P=0.013)和手术时间(OR 1.006,95%CI 1.001～1.012,P=0.026)是围术期出血事件的独立危险因素。结论术前长期服用抗血栓药物的患者,当前围术期抗栓药物管理不够规范,需要进一步加强。对于年龄>65岁、合并外周血管疾病或拟行大手术的患者,围术期需警惕MACCE。术前采用阿司匹林联合替格瑞洛的用药方案和手术时间长是围术期出血事件的独立危险因素。

关键词(KeyWords)： 抗血栓药物;围术期;主要不良心脑血管事件;出血事件

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 张鸿,王梓凝,李怀瑾,朱珊,赵宇彤,龚艳君,蒋捷

参考文献(References)：

• [1]Zhou M,Wang H,Zhu J,et al.Cause-specific mortality for 240causes in China during 1990-2013:a systematic subnational analysis for the global burden of disease study 2013[J].Lancet,2016,387(10015):251-272.
• [2]Go AS,Mozaffarian D,Roger VL,et al.Executive summary:heart disease and stroke statistics—2013 update[J].Circulation,2013,127(1):143-152.
• [3]陈艳,袁晋青.经皮冠状动脉介入治疗术后接受非心脏外科手术患者的抗血小板药物治疗[J].中国介入心脏病学杂志,2016,24(11):655-660.
• [4]Oltmann SC,Alhefdhi AY,Rajaei MH,et al.Antiplatelet and anticoagulant medications significantly increase the risk of postoperative hematoma:review of over 4500 thyroid and parathyroid procedures[J].Ann Surg Oncol,2016,23(9):2874-2882.
• [5]Rossini R,Tarantini G,Musumeci G,et al.A multidisciplinary approach on the perioperative antithrombotic management of patients with coronary stents undergoing surgery:surgery after stenting 2[J].JACC Cardiovasc Interv,2018,11(5):417-434.
• [6]Torn M,Rosendaal FR-Oral anticoagulation in surgical procedures:risks and recommendations[J].Br J Haematol,2003,123(4):676-682.
• [7]Fleisher LA,Fleischmann KE,Auerbach AD,et al.2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery:executive summary[J].Circulation,2014,130(24):2215-2245.
• [8]Godier A,Garrigue D,Lasne D,et al.Management of antiplatelet therapy for non-elective invasive procedures or bleeding complications:proposals from the French Working Group on Perioperative Haemostasis(GIHP)and the French Study Group on Thrombosis and Haemostasis(GFHT),in collaboratio[J].Arch Cardiovasc Dis,2019,112(3):199-216.
• [9]H or nor MA,Duane TM,Ehlers AP,et al.American college of surgeons' guidelines for the pericperative ianagement of antithrombotic medication[J].J Am Coll Surg,2018,227(5):521-536.e1.
• [10]Widimsky P,Mot'ovska Z,Havluj L,et al.Perioperative cardiovascular complications versus perioperative bleeding in consecutive patients with known cardiac disease undergoing noncardiac surgery.Focus on antithrombotic medication.The PRAGUE-14registry[J].Netherlands Hear J,2014,22(9):372-379.
• [11]Valle JA,Graham L,DeRussy A,et al.Triple antithrombotic therapy and outcomes in post-PCI patients undergoing non-cardiac surgery[J].World J Surg,2017,41(2):423-432.
• [12]Howell SJ,Hoeks SE,West RM,et al.Prospective observational cohort study of the association between antiplatelet therapy,bleeding and thrombosis in patients with coronary stents undergoingnoncardiac surgery[J].Br J Anaesth,2019,122(2):170-179.
• [13]Armstrong EJ,Graham LA,Waldo SW,et al.Incomplete revascularization is associated with an increased risk for major adverse cardiovascular events among patients undergoing noncardiac surgery[J].JACC Cardiovasc Interv,2017,10(4):329-338.
• [14]Hawn MT,Graham LA,Richman JS,et al.Risk of major adverse cardiac events following noncardiac surgery in patients with coronary stents[J].JAMA,2013,310(14):1462-1472.
• [15]Anwaruddin S,Askari AT,Saudye H,et al.Characterization of post-operative risk associated with prior drug-eluting stent use[J].JACC Cardiovasc Interv,2009,2(6):542-549.
• [16]Hong SJ,Kim MJ,Kim JS,et al.Effect of perioperative antiplatelet therapy on outcomes in patients with drug-eluting stents undergoing elective noncardiac surgery[J].Am J Cardiol,2019,123(9):1414-1421.
• [17]Egholm G,Thim T,Olesen K,et al.Dual anti-platelet therapy after coronary drug-eluting stent implantation and surgery-associated major adverse events[J].Thromb Haemost,2016,116(1):172-180.
• [18]Rossini R,Musumeci G,Capodanno D,et al.Perioperative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery[J].Thromb Haemost,2015,113(2):272-282.
• [19]Columbo JA,Lambour AJ,Sundling RA,et al.A meta-analysis of the impact of aspirin,clopidogrel,and dual antiplatelet therapy on bleeding complications in noncardiac surgery[J].Ann Surg,2018,267(1):1-10.
• [20]张鹏,兰天珩,周一鸣,等.胃癌根治术围手术期并发症危险因素分析[J].中华胃肠外科杂志,2019,22(8):736-741.
• [21]Amri M,Naouar S,Ben Khalifa B,et al.Predictive factors of bleeding and fever after percutaneous nephrolithotomy[J].Tunis Med,2019,97(5):667-674.
• [22]Spivak H,Azran C,Spectre G,et al.Sleeve gastrectomy postoperative hemorrhage is linked to type-2 diabetes and not to surgical technique[J].Obes Surg,2017,27(11):2927-2932.
• [23]Versteeg HH,Heemskerk JW,Levi M,et al.New fundamentals in hemostasis[J].Physiol Rev,2013,93(1):327-358.
• [24]Brem H,Tomic-Canic M.Cellular and molecular basis of wound healing in diabetes[J].J Clin Invest,2007,117(5):1219-1222.
• [25]Childers CP,Maggard-Gibbons M,Ulloa JG,et al.Perioperative management of antiplatelet therapy in patients undergoing noncardiac surgery following coronary stent placement:a systematic review[J].Syst Rev,2018,7(1):4.
• [26]Newman JD,Wilcox T,Smilowitz NR,et al.Influence of diabetes on trends in perioperative cardiovascular events[J].Diabetes Care,2018,41(6):1268-1274.
• [27]Alazawi W,Pirmadjid N,Lahiri R,et al.Inflammatory and immune responses to surgery and their clinical impact[J].Ann Surg,2016,264(1):73-80.
• [28]Khorgami Z,Jackson TN,Aminian A,et al.Early cardiac complications after bariatric surgery:does the type of procedure matter[J]?Surg Obes Relat Dis,2019,15(7):1132-1137.
• [29]Araguas MA,Herrera A,Garrido I,et al.Risk factors for major adverse cardiovascular events after osteoporotic hip fracture repair surgery[J].Injury,2020,51 Suppl 1:S30-36.
• [30]Magapu P,Haskard D,Fisher M.A review of the peri-operative risk stratification assessment tools used for the prediction of cardiovascular complications in non-cardiac surgery[J].Perfusion,2016,31(5):358-365.
• [31]van Hattum ES,Algra A,Lawson JA,et al.Bleeding increases the risk of ischemic events in patients with peripheral arterial disease[J].Circulation,2009,120(16):1569-1576.